|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Nosocomial Infections - The Need for New Gram-negative Drugs
Datamonitor, March 2007, Pages: 162
In the US and Europe, an estimated 5–10% of patients are expected to develop an infection during their hospital stay. The four main types of infections that occur within the hospital setting are urinary tract infections, hospital acquired pneumonia, surgical site infections and blood-stream infections, accounting for approximately 35%, 15%, 14% and 10% respectively.
Scope of this title:
Overview of the epidemiological trends of the four main types of nosocomial infections. An analysis of the incidence and antimicrobial susceptibilities of etiologic agents An estimation of the current antibiotic treatment costs and market size by infection site An assessment of key unmet needs and new product development
Highlights of this title:
Over the past decades, there has been a notable rise in the number of hospital infections caused by gram-positive bacteria such as Staphylococcus aureus and enterococci. However, the most important observation has been that of the rising numbers of gram positive bacteria resistant to several of the currently available antibiotics. Although gram-positive organisms account for the majority of nosocomial infections, there has been a big increase in multi-drug resistant gram-negative bacteria such as extended-spectrum beta-lactamase (ESBL) producing E. coli and K. pneumoniae and strains of P. aeruginosa and A. baumannii resistant to all currently available antimicrobials. The majority of newly introduced products and products in late stage development target gram-positive bacteria such as MRSA. Although these agents have been welcomed by the infectious disease community, we believe there is a significant opportunity for new antibacterials which can treat multi-drug resistant gram-negative organisms.
Reasons to order your copy:
Identify the key factors that determine treatment choice in nosocomial infections Examine the remaining and emerging unmet needs in the nosocomial infections market and identify opportunities for new product development Gain an overview of market size and treatment cost of the four most common infections in terms of value and patient numbers
Customers who bought this item also bought
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
Commercial Perspectives: Vaccines - Nosocomial Pathogens
Urinary Tract Infections: Growing Resistance Rates bring Opportunities for Both New and Old Drugs
Stakeholder Opinions: Skin and Soft Tissue Infections
Bacterial Infections: An Epidemiological Overview
Bacterial Infections: An Epidemiological Overview
Infections and Wound Treatments
Identifying Drug-Resistant Bacterial Infections: Opportunity and Activity in the Diagnostics Arena
Infections Urinary Tract Infections
Stakeholder Opinions: Skin Infections - Where In The Antibacterial Lifecycle?
Stakeholder Opinions: Urinary Tract Infections - Ciprofloxacin Leads the Way
Stakeholder Insight: Invasive Fungal Infections - Options Outweigh Replacements
|
|
|
|
